- Home
- LRE vs UNCY Comparison
LRE vs UNCY Comparison
Compare LRE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | UNCY |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 126.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRE | UNCY |
|---|---|---|
| Price | $1.32 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 7.3K | ★ 362.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $3.71 |
| 52 Week High | $2.97 | $11.00 |
Technical Indicators
Market Signals| Indicator | LRE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 49.58 |
| Support Level | $1.29 | $5.35 |
| Resistance Level | $1.45 | $6.95 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 37.30 | 25.08 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.